(Public, NASDAQ:CRME)   Watch this stock  
Find more results for CRME
-0.06 (-0.62%)
Mar 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.62 - 9.81
52 week 5.84 - 11.31
Open 9.72
Vol / Avg. 63,488.00/62,133.00
Mkt cap 160.99M
P/E     -
Div/yield     -
EPS -1.25
Shares 16.52M
Beta 1.62
Inst. own 283%
Mar 12, 2015
Q4 2014 Cardiome Pharma Corp Earnings Call - 8:00AM EDT - Add to calendar
Mar 12, 2015
Q4 2014 Cardiome Pharma Corp Earnings Release Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -55.94% 105.81%
Operating margin -44.49% 91.71%
EBITD margin - -295.88%
Return on average assets -35.09% 10.36%
Return on average equity -67.90% 31.30%
Employees 75 -
CDP Score - -


+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company�s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.

Officers and directors

Robert W. Rieder Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Jennifer Archibald Chief Financial Officer
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
Karim Lalji Chief Commercial Officer
Bio & Compensation  - Reuters
Richard M. Glickman Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
W. James O'Shea Director
Bio & Compensation  - Reuters
Peter W. Roberts CPA Independent Director
Bio & Compensation  - Reuters
Harold H. Shlevin M.D., Ph.D., Independent Director
Age: 63
Bio & Compensation  - Reuters